

**THE FOLLOWING WERE APPROVED**

**INVESTIGATOR:** Laura E. Hays Ph.D.  
Suite 201  
1801 Willamette Street  
Eugene, Oregon 97401

**BOARD ACTION DATE:** 06/13/2013  
**PANEL:** 4  
**STUDY APPROVAL EXPIRES:** 06/13/2014  
**STUDY NUM:** 1139633  
**WIRB PRO NUM:** 20130937  
**INVEST NUM:** 182611  
**WO NUM:** 1-783443-1  
**CONTINUING REVIEW:** Annually  
**SITE STATUS REPORTING:** Annually

**SPONSOR:** Fanconi Anemia Research Fund  
**PROTOCOL NUM:** FARF-DE-001-2013  
**AMD. PRO. NUM:**  
**TITLE:**  
Reducing the burden of squamous cell carcinoma in Fanconi anemia

**APPROVAL INCLUDES:**

Investigator  
Protocol  
Study Questionnaire #10954819.0 - As Submitted  
Assent Information Sheet - Up to age 14  
Consent Form [S0]  
Consent Information Sheet - Adolescents Over 14 and Adults #10954817.0  
Advertisement - For people with Fanconi anemia #10949337.0 - As Submitted

**WIRB APPROVAL IS GRANTED SUBJECT TO:**

The Board requires that all subjects must be able to consent for themselves to be enrolled in this study. This means that you cannot enroll incapable subjects who require enrollment by consent of a legally authorized representative.

**WIRB HAS APPROVED THE FOLLOWING LOCATIONS TO BE USED IN THE RESEARCH:**

Camp Sunshine, 35 Acadia Road, Casco, Maine 04015

**If the PI has an obligation to use another IRB for any site listed above and has not submitted a written statement from the other IRB acknowledging WIRB's review of this research, please contact WIRB's Client Services department.**

**ALL WIRB APPROVED INVESTIGATORS MUST COMPLY WITH THE FOLLOWING:**

1. Conduct the research in accordance with the protocol, applicable laws and regulations, and the principles of research ethics as set forth in the Belmont Report.
2. Although a participant is not obliged to give his or her reasons for withdrawing prematurely from the clinical trial, the investigator should make a reasonable effort to ascertain the reason, while fully respecting the participant's rights.
3. Unless consent has been waived, conduct the informed consent process without coercion or undue influence, and provide the potential subject sufficient opportunity to consider whether or not to participate. (Due to the unique circumstances of research conducted at international sites outside the United States and Canada where WIRB approved materials are translated

IF YOU HAVE ANY QUESTIONS, CONTACT WIRB AT 1-800-562-4789

This is to certify that the information contained herein is true and correct as reflected in the records of the Western Institutional Review Board (WIRB), OHRP/FDA parent organization number IORG 0000432, IRB registration number IRB00000533. WE CERTIFY THAT WIRB IS IN FULL COMPLIANCE WITH GOOD CLINICAL PRACTICES AS DEFINED UNDER THE U.S. FOOD AND DRUG ADMINISTRATION (FDA) REGULATIONS, U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES (HHS) REGULATIONS, AND THE INTERNATIONAL CONFERENCE ON HARMONISATION (ICH) GUIDELINES.



into the local language, the following requirements regarding consent forms bearing the WIRB approval stamp and regarding certification of translations are not applicable.)

- a. Use only the most current consent form bearing the WIRB "APPROVED" stamp.
  - b. Provide non-English speaking subjects with a certified translation of the approved consent form in the subject's first language. The translation must be approved by WIRB unless other arrangements have been made and approved by WIRB.
  - c. Obtain pre-approval from WIRB for use of recruitment materials and other materials provided to subjects.
4. Enrollment of limited readers and non-readers: unless consent has been waived or the protocol excludes enrollment of limited readers or non-readers, involve an impartial witness in the consent process when enrolling limited or non-readers and document the participation of the impartial witness using the designated signature lines on the WIRB-approved consent form. In the absence of designated signature lines, download the WIRB standard impartial witness form from [www.wirb.com](http://www.wirb.com).
  5. Obtain pre-approval from WIRB for changes in research.
  6. Obtain pre-approval from WIRB for planned deviations and changes in research activity as follows:
    - If the research is federally funded, conducted under an FWA, or is a clinical investigation of a drug or biologic, then all planned protocol deviations must be submitted to WIRB for review and approval prior to implementation except where necessary to eliminate apparent immediate hazards to the human subjects [(DHHS 45 CFR § 46.103(b)(4); (FDA 21 CFR § 56.108(a)(4); ICH 3.3.7].
    - However, if the research is a clinical investigation of a device and the research is not federally funded and not conducted under an FWA, then only planned protocol deviations that may adversely affect the rights, safety or welfare of subjects or the integrity of the research data should be submitted to WIRB for review and approval prior to implementation except where necessary to eliminate apparent immediate hazards to the human subjects [(DHHS 45 CFR § 46.103(b)(4); (FDA 21 CFR § 56.108(a)(4); ICH 3.3.7].

The reason for these different requirements regarding planned protocol deviations is that the Office for Human Research Protections (OHRP) and the Food and Drug Administration (FDA) drug and biologic divisions have adopted the regulatory interpretation that every planned protocol deviation is a change in research that needs prior IRB review and approval before implementation; however, the FDA device division operates under a distinct regulation (See 21 CFR 812.150(a)(4).

Deviations necessary to eliminate apparent immediate hazards to the human subjects should be reported within 10 days.

7. Promptly report to WIRB all unanticipated problems (adverse events, protocol deviations and violations and other problems) that meet all of the following criteria:
  - a. Unexpected (in terms of nature, severity or frequency);
  - b. Related or possibly related to participation in the research; and
  - c. Suggests that the research places subjects or others at a greater risk of harm than was previously known or recognized.

Please go to [www.wirb.com](http://www.wirb.com) for complete definitions and forms for reporting.

8. Provide reports to WIRB concerning the progress of the research, when requested.
9. Ensure that prior to performing study-related duties, each member of the research study team has had training in the protection of human subjects appropriate to the processes required in the approved protocol.

**Federal regulations require that WIRB conduct continuing review of approved research. You will receive Continuing Review Report forms from WIRB. These reports must be returned even though your study may not have started.**

#### **DISTRIBUTION OF COPIES:**

##### **Contact, Company**

Laura E Hays Ph.D., Fanconi Anemia Research Fund  
Amy Frohnmayer, Fanconi Anemia Research Fund